Beta-secretase (BACE) as a drug target for Alzheimer's disease.
about
Evidence for natural antisense transcript-mediated inhibition of microRNA functionAlzheimer's therapeutics: translation of preclinical science to clinical drug developmentBACE1 and presenilin: two unusual aspartyl proteases involved in Alzheimer's diseaseBACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity.Targeting Abeta and tau in Alzheimer's disease, an early interim reportInhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies.BACE1 inhibitory activity of fungal endophytic extracts from Malaysian medicinal plantsNeuroprotective properties of chitosan and its derivatives.Involvement of receptor tyrosine kinase Tyro3 in amyloidogenic APP processing and β-amyloid deposition in Alzheimer's disease models.Exploring the binding of BACE-1 inhibitors using comparative binding energy analysis (COMBINE).N-{N-[2-(3,5-Difluorophenyl)acetyl]-(S)-alanyl}-(S)-phenylglycine tert-butyl ester (DAPT): an inhibitor of γ-secretase, revealing fine electronic and hydrogen-bonding features.HIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos SantosDesign and characterization of a new cell-permeant inhibitor of the beta-secretase BACE1.Applications of molecular imaging.Postsynaptic target specific synaptic dysfunctions in the CA3 area of BACE1 knockout mice.Identification of BACE2 as an avid ß-amyloid-degrading proteasePhysiologically generated presenilin 1 lacking exon 8 fails to rescue brain PS1-/- phenotype and forms complexes with wildtype PS1 and nicastrin.Relevance of amyloid precursor-like protein 2 C-terminal fragments in pancreatic cancer cells.The physics of the interactions governing folding and association of proteins.Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease.A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysisMemantine in the treatment of mild-to-moderate Alzheimer's disease.Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation.Regulation of proBACE1 by glycosaminoglycans.Neuronal protein trafficking associated with Alzheimer disease: from APP and BACE1 to glutamate receptorsBACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampusAspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy.Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain.Plasminogen enhances neuritogenesis on laminin-1.AβPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for alzheimer's disease.Oxidative stress and β-amyloid protein in Alzheimer's disease.Membrane trafficking pathways in Alzheimer's disease.Roles of AMP-activated protein kinase in Alzheimer's disease.Opioid system and Alzheimer's disease.Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity.Imidazoline derivatives: a patent review (2006--present).Nanotechnology based theranostic approaches in Alzheimer's disease management: Current status and future perspective.The Metalloprotease Meprin β Is an Alternative β-Secretase of APP.2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927.
P2860
Q21184035-FBA78BC0-8845-49F9-BF67-8CF0BE2F0D65Q26829267-D86DEE38-7500-462D-ACF6-46104D27B9C6Q28257726-346804DC-9010-4B48-9103-2E4A01EE30DEQ30483997-462743E9-2CD1-49A7-90D2-87019A8BE96FQ33275047-0EA1708E-4568-4385-A27E-72C88B9D7001Q33829008-D5ED6127-63E6-43F2-A3D1-E8242F3F35DDQ33836358-E8763880-16FB-4BE7-956F-18DE52E53314Q34029099-50BBE97A-9C67-4870-9714-30A392A2D9A9Q34061851-9D5E925E-806A-4C8F-AF9F-338E44988CC1Q34305878-2AEEA1B9-963F-4ADE-89A8-5B7C2F78AD7CQ34394583-BF33D45E-8D61-469E-B685-7C3338C8C192Q34457604-0393513C-3DFE-4A53-98B4-A5BD458D354FQ34878614-C3EA1B6F-0052-4A3B-91D6-BCE6B137A68AQ35048864-AE8443D9-9F7E-41FD-AAD1-248FFA26F524Q35082412-4FDBC1F5-3AF9-41C2-87BB-44775001693EQ35122722-9FDDDA9C-E969-43AD-9DFB-A19984F43F46Q36316174-DC2B4A58-4386-43C9-A2E3-36CAE8DBA593Q36320612-B168E229-DAAF-43AB-8EBC-7DE32A973F8BQ36350742-79C0B502-B661-44EA-9715-2BF53FAA4D4CQ36420053-805580D7-2E19-41E1-A380-9E141053E1F2Q36688776-B06A8329-C6F2-4B19-A2A5-EC5947D96370Q36690193-B44E6AA9-5B83-441D-AA71-97193D3CB5DDQ36719691-6912F3A7-8D48-4A17-A9AA-E3AFBDC5E80AQ36852202-56CB9083-7BED-4400-B832-D516F0BD22ADQ37103048-EEB266A2-D159-4817-BBE0-0CEE786075ADQ37174236-53FE2B1B-DE88-4385-BE46-7794824C086FQ37309641-C3790843-6FEC-482E-AE32-3E4A5180004AQ37334816-B3BF2280-A3ED-4694-87CB-04E155BDB642Q37394529-5315C57F-4FA0-4B17-95C7-D51D81F72380Q37462808-DABEC5A6-2437-4815-9F75-5BC95B6F6062Q37677861-DBF3389D-F89A-4C51-A2B6-5D5082D9CF39Q37928994-AAB20B69-707A-4248-AE39-0A62DA72720EQ37978006-AF254BB6-83BC-43D5-AABF-D2E2D064A197Q37988399-B859BDFC-0570-4C8D-A51F-D8BEE6ECB93CQ38004941-6F19D5B1-00C6-4A94-998C-D6034E0E7E08Q38026045-56FDBC0E-0A71-4B66-81AA-67FB1ABA9B10Q38045922-CBA72616-B5FE-474E-84C2-D46C137D12FEQ38686370-7674DFCB-49DE-4130-B385-CCB797B14FEBQ39095782-7A2688A0-598D-4878-801B-4F07CDCF8E9BQ39244962-3E502554-DA22-40D0-9A9E-13CFD53B7EE3
P2860
Beta-secretase (BACE) as a drug target for Alzheimer's disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Beta-secretase (BACE) as a drug target for Alzheimer's disease.
@ast
Beta-secretase (BACE) as a drug target for Alzheimer's disease.
@en
type
label
Beta-secretase (BACE) as a drug target for Alzheimer's disease.
@ast
Beta-secretase (BACE) as a drug target for Alzheimer's disease.
@en
prefLabel
Beta-secretase (BACE) as a drug target for Alzheimer's disease.
@ast
Beta-secretase (BACE) as a drug target for Alzheimer's disease.
@en
P1476
Beta-secretase (BACE) as a drug target for Alzheimer's disease.
@en
P2093
Robert Vassar
P304
P356
10.1016/S0169-409X(02)00157-6
P407
P577
2002-12-01T00:00:00Z